Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Colorectal cancer (CRC) is the second most common type of malignancy in Western nations. Improvements in surgical and radiotherapeutic techniques and the increased availability of new cytotoxic drugs have improved outcome, but 50% of patients still die from recurrent or metastatic disease. Several features of its natural history render CRC a good candidate for gene therapy. Techniques include gene replacement, virus-directed enzyme-prodrug therapy, immune manipulation and virotherapy, all of which have entered clinical trials.

Original publication

DOI

10.1038/nrc1147

Type

Journal article

Journal

Nat Rev Cancer

Publication Date

08/2003

Volume

3

Pages

615 - 622

Keywords

Clinical Trials as Topic, Colorectal Neoplasms, Enzymes, Genetic Therapy, Genetic Vectors, Humans, Immunotherapy, Models, Biological, Prodrugs, Viruses